AR048341A1 - Moduladores cannabinoides de tetrahidro-indazol - Google Patents
Moduladores cannabinoides de tetrahidro-indazolInfo
- Publication number
- AR048341A1 AR048341A1 ARP050101196A ARP050101196A AR048341A1 AR 048341 A1 AR048341 A1 AR 048341A1 AR P050101196 A ARP050101196 A AR P050101196A AR P050101196 A ARP050101196 A AR P050101196A AR 048341 A1 AR048341 A1 AR 048341A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- halogen
- positions
- optionally substituted
- alkylene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente trata de moduladores cannabinoides de tetrahidroindazol, y un método para usarlo en el tratamiento, mejoramiento o prevencion de un sindrome, desorden o enfermedad intermediado por un receptor cannabinoide. Reivindicacion 1: Un compuesto que tiene una estructura de acuerdo con la formula (1): en la cual la línea punteada entre las posiciones 2-3 y las posiciones 3a-7a en la formula (1) representan ubicaciones para los dos dobles enlaces presentes cuando X1R1 está presente; las líneas punteadas entre las posiciones 3-3a y las posiciones 7a-1 en la formula (1) representan ubicaciones para los dos dobles enlaces presentes cuando está presente X2R2; la línea punteada entre las posiciones 7 y X4R4 en la formula (1) representa la ubicacion para un doble enlace; X1 está ausente o es alquileno inferior; X2 está ausente o es alquileno inferior; donde unicamente están presentes uno de X1R1 y X2R2; X3 está ausente, o es alquileno inferior, alquilideno inferior o -NH- ; cuando la línea punteada entre las posiciones 7 y X4R4 está ausente, X4 está ausente o es alquileno inferior; cuando la línea punteada entre las posiciones 7 y X4R4 está presente, X4 está ausente; X5 está ausente o es alquileno inferior; R1 está seleccionado del grupo que consiste en arilo, cicloalquilo C3-12, o heterociclilo, cualquiera de los cuales está opcionalmente sustituido en una o más posiciones con halogeno, alquilo inferior, hidroxi o alcoxi inferior; R2 está seleccionado del grupo que consiste en arilo, cicloalquilo C3-12, o heterociclilo, cualquiera de los cuales está opcionalmente sustituido en una o más posiciones con halogeno, alquilo inferior, hidroxi o alcoxi inferior; R3 es como se muestra en el grupo de formulas (2), cuando la línea punteada entre las posiciones 7 y X4R4 está ausente, R4 es H, hidroxi, alquilo inferior, alcoxi inferior, halogeno, arilo opcionalmente sustituido en una o más posiciones con hidroxi, alquilo inferior, alcoxi inferior o halogeno, heterociclilo opcionalmente sustituido en una o más posiciones con hidroxi, alquilo inferior, alcoxi inferior o halogeno, o cicloalquilo C3-12 opcionalmente sustituido en una o más posiciones con hidroxi, alquilo inferior, alcoxi inferior o halogeno; cuando la línea punteada entre las posiciones 7 y X4R4 está presente, R4 es CH-arilo es donde arilo está opcionalmente sustituido en una o más posiciones con hidroxi, alquilo inferior, alcoxi inferior o halogeno; o CH-heterociclilo en donde el heterociclilo está opcionalmente sustituido en una o más posiciones con hidroxi, alquilo inferior, alcoxi inferior o halogeno; R5 es H, hidroxi, alquilo inferior, alcoxi inferior, hidroxi-alquileno inferior-carboxi, alcoxicarbonilo, ariloxicarbonilo, aril-alcoxicarbonilo, NHR10, C(O)NR11R11a, -O-C(O)-R12, oxo, o -C(O)R13; R6 está ausente, o es -CH(R6a)-; R6a es H, alquilo inferior, o arilo opcionalmente sustituido con uno o más de halogeno, hidroxi, alcoxi inferior, carboxi o alcoxicarbonilo; R7 es alcoxi inferior, arilo opcionalmente sustituido con uno más hidroxi, halogeno, alquilo inferior, carboxi, alcoxicarbonilo, alcoxi inferior, hidroxi-alquileno-, -NH(R6a), ariloxi, arilalcoxi, o aril-alquileno inferior, cicloalquilo C3-12 opcionalmente sustituido con uno o mas hidroxi, halogeno, alquilo inferior, alquilo inferior-aminocarbonilo, carboxi, alcoxicarbonilo, alcoxi inferior, alcoxi inferior-alquileno inferior, hidroxi-alquileno-, ariloxi, arilalcoxi, arilalcoxi-alquileno inferior- opcionalmente sustituido en el arilo con uno o más hidroxi, halogeno o alquilo inferior, o aril-alquileno inferior, heterociclilo opcionalmente sustituido con uno o más hidroxi, halogeno, alquilo inferior, carboxi, alcoxicarbonilo, alcoxi inferior, alcoxi inferior-alquileno inferior-, hidroxi-alquileno-, ariloxi o arilalcoxi; R8, R8a, R9 y R9a, son cada uno individualmente H, alquilo inferior, -NHR15, arilo opcionalmente sustituido con uno o más hidroxi, halogeno, -NH(R6a), -SO2-NH(R6a), alquilo inferior, carboxi, alcoxicarbonilo, alcoxi inferior, hidroxi-alquileno-, ariloxi o arilalcoxi, cicloalquilo C3-12 opcionalmente sustituido con uno o más hidroxi, halogeno, amino, alquilo inferior, carboxi, alcoxicarbonilo, alcoxi inferior, hidroxi-alquileno-, ariloxi, arilalcoxi, o alquileno inferior, o heterociclilo opcionalmente sustituido con uno o más hidroxi, halogeno, amino, alquilo inferior, carboxi, alcoxicarbonilo, alcoxi inferior, hidroxi- alquileno-, ariloxi o arilalcoxi; R10 es H, alcoxicarbonilo C1-10 opcionalmente sustituido en una o más posiciones con hidroxi, halogeno o arilo, -C(O)CF3, -SO2-NR14R14a, -C(O)-heterociclilo opcionalmente sustituido en una o más posiciones con hidroxi, halogeno, o arilo, -C(O)NR14R14a, -SO2-arilo, -SO2R14, o SO2NR14R14a, R11, R11a, R12, R13, R14 y R14a y R15 son cada uno individualmente H, alquilo C1-10, heterociclilo, cicloalquilo C3-12, o arilo opcionalmente sustituido con alquilo inferior, hidroxi, alcoxi, halogeno-SO2-N(R6a)2, heterociclilo o aril-alquileno inferior-; Z1 está ausente, -NH-, o es alquileno inferior opcionalmente sustituido en una o más posiciones con halogeno, hidroxi,. alcoxi inferior, carboxi o alcoxicarbonilo inferior; Z2 está ausente, o es alquileno inferior opcionalmente sustituido en una o más posiciones con arilo, cicloalquilo, halogeno, hidroxi, alquilo inferior, alcoxi inferior, carboxi, alcoxicarbonilo o arilo, o una sal, isomero, profármaco, metabolito o polimorfo farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55589004P | 2004-03-24 | 2004-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR048341A1 true AR048341A1 (es) | 2006-04-19 |
Family
ID=34965110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050101196A AR048341A1 (es) | 2004-03-24 | 2005-03-28 | Moduladores cannabinoides de tetrahidro-indazol |
Country Status (22)
Country | Link |
---|---|
US (2) | US7452997B2 (es) |
EP (1) | EP1735286B1 (es) |
JP (1) | JP4825792B2 (es) |
CN (1) | CN1956964B (es) |
AR (1) | AR048341A1 (es) |
AT (1) | ATE540027T1 (es) |
AU (1) | AU2005228868B2 (es) |
BR (1) | BRPI0509207A (es) |
CA (1) | CA2561305C (es) |
CR (1) | CR8701A (es) |
DK (1) | DK1735286T3 (es) |
EA (1) | EA010887B1 (es) |
EC (1) | ECSP066877A (es) |
ES (1) | ES2378071T3 (es) |
IL (1) | IL178290A0 (es) |
MX (1) | MXPA06011017A (es) |
NO (1) | NO20064810L (es) |
PL (1) | PL1735286T3 (es) |
PT (1) | PT1735286E (es) |
TW (1) | TW200602324A (es) |
WO (1) | WO2005095353A1 (es) |
ZA (1) | ZA200608808B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
US7888381B2 (en) | 2005-06-14 | 2011-02-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof |
US8378096B2 (en) | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
PL1931335T3 (pl) * | 2005-09-23 | 2010-07-30 | Janssen Pharmaceutica Nv | Modulatory heksahydrocyklooktylopirazolokannabinoidowe |
CA2623745A1 (en) * | 2005-09-23 | 2007-04-05 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
US7825151B2 (en) * | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
US8378117B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
CN101312724A (zh) * | 2005-09-23 | 2008-11-26 | 詹森药业有限公司 | 四氢-吲唑基大麻素调节剂 |
CN101312952B (zh) | 2005-09-23 | 2012-12-26 | 詹森药业有限公司 | 四氢-环戊二烯并吡唑大麻素调节剂 |
WO2007095513A1 (en) * | 2006-02-14 | 2007-08-23 | Janssen Pharmaceutica, Nv | Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators |
US20070254911A1 (en) * | 2006-03-27 | 2007-11-01 | Mingde Xia | Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators |
WO2007112402A1 (en) * | 2006-03-27 | 2007-10-04 | Janssen Pharmaceutica N.V. | Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators |
WO2008054508A2 (en) * | 2006-04-13 | 2008-05-08 | Alza Corporation | Stable nanosized amorphous drug |
JP2010509201A (ja) * | 2006-11-03 | 2010-03-25 | グレンマーク・ファーマシューティカルズ・エスエー | 新規なカンナビノイド受容体リガンド、およびこれらを含む薬剤組成物、およびこれらの調製方法 |
EP1935420A1 (en) * | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors |
CA2681384A1 (en) * | 2007-03-21 | 2008-09-25 | Janssen Pharmaceutica N.V. | Method for treating cb2 receptor mediated pain |
EP2139326A4 (en) * | 2007-03-21 | 2011-06-15 | Janssen Pharmaceutica Nv | METHOD OF TREATING PAIN INDUCED BY A CB2 RECEPTOR |
UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
US8338623B2 (en) * | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US7943653B2 (en) * | 2007-08-13 | 2011-05-17 | Janssen Pharmaceutica N.V. | Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators |
CA2794054C (en) * | 2008-01-08 | 2014-11-25 | Purdue Pharma L.P. | Proline analogs as ligands for cannabinoid receptors |
US20090215850A1 (en) * | 2008-02-27 | 2009-08-27 | Mingde Xia | Method for treating cb2 receptor mediated pain |
WO2010034649A1 (en) * | 2008-09-25 | 2010-04-01 | F. Hoffmann-La Roche Ag | 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US10435375B2 (en) | 2015-05-05 | 2019-10-08 | Northwestern University | CXCR4 chemokine receptor modulators |
WO2017034872A1 (en) * | 2015-08-25 | 2017-03-02 | Janssen Pharmaceutica Nv | Indazole derivatives useful as cb-1 inverse agonists |
CN105367498B (zh) * | 2015-11-11 | 2019-05-17 | 中国农业大学 | 吡唑并环-3-甲酰胺类似物及其制备和应用 |
CN106397218A (zh) * | 2016-09-04 | 2017-02-15 | 王际菊 | S‑α‑环己基苯甲胺 |
WO2020008317A1 (en) * | 2018-07-03 | 2020-01-09 | Janssen Pharmaceutica Nv | Acylsufonamide compounds useful as ep3 receptor antagonists |
TWI768465B (zh) * | 2019-09-12 | 2022-06-21 | 大陸商四川海思科製藥有限公司 | 四氫吲唑衍生物及其製備 |
WO2021047583A1 (zh) * | 2019-09-12 | 2021-03-18 | 四川海思科制药有限公司 | 一种三环吡唑衍生物及其制备 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1052111B (it) * | 1972-02-29 | 1981-06-20 | Acraf | Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati |
US3895025A (en) * | 1973-03-29 | 1975-07-15 | Du Pont | 2-Benzimidazolethiol preparation |
WO1986007357A2 (en) * | 1985-06-14 | 1986-12-18 | Upjohn Co | Cyclopentapyrazole and tetrahydroindazole compounds |
US4861777A (en) * | 1987-09-11 | 1989-08-29 | Mitsubishi Kasei Corporation | Pyrazole derivative and insecticidal and miticidal composition containing the derivative as active ingredient |
JPH06306053A (ja) * | 1993-01-29 | 1994-11-01 | Sagami Chem Res Center | 3−アゾールカルボン酸誘導体の製造方法及びその中間体 |
US5532237A (en) * | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
US6410533B1 (en) | 2000-02-10 | 2002-06-25 | Genzyme Corporation | Antibacterial compounds |
JP2004502642A (ja) * | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
EP1448557A4 (en) * | 2001-10-26 | 2005-02-02 | Univ Connecticut | HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS |
CA2480856A1 (en) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
-
2005
- 2005-03-23 ES ES05732229T patent/ES2378071T3/es active Active
- 2005-03-23 US US11/087,943 patent/US7452997B2/en not_active Expired - Fee Related
- 2005-03-23 TW TW094108873A patent/TW200602324A/zh unknown
- 2005-03-23 CA CA2561305A patent/CA2561305C/en not_active Expired - Fee Related
- 2005-03-23 AU AU2005228868A patent/AU2005228868B2/en not_active Ceased
- 2005-03-23 CN CN2005800160828A patent/CN1956964B/zh not_active Expired - Fee Related
- 2005-03-23 EP EP05732229A patent/EP1735286B1/en active Active
- 2005-03-23 WO PCT/US2005/009819 patent/WO2005095353A1/en active Application Filing
- 2005-03-23 EA EA200601760A patent/EA010887B1/ru not_active IP Right Cessation
- 2005-03-23 PL PL05732229T patent/PL1735286T3/pl unknown
- 2005-03-23 MX MXPA06011017A patent/MXPA06011017A/es unknown
- 2005-03-23 DK DK05732229.9T patent/DK1735286T3/da active
- 2005-03-23 JP JP2007505172A patent/JP4825792B2/ja not_active Expired - Fee Related
- 2005-03-23 AT AT05732229T patent/ATE540027T1/de active
- 2005-03-23 BR BRPI0509207-8A patent/BRPI0509207A/pt not_active IP Right Cessation
- 2005-03-23 PT PT05732229T patent/PT1735286E/pt unknown
- 2005-03-28 AR ARP050101196A patent/AR048341A1/es not_active Application Discontinuation
-
2006
- 2006-09-22 EC EC2006006877A patent/ECSP066877A/es unknown
- 2006-09-25 IL IL178290A patent/IL178290A0/en unknown
- 2006-10-20 CR CR8701A patent/CR8701A/es unknown
- 2006-10-23 ZA ZA200608808A patent/ZA200608808B/en unknown
- 2006-10-23 NO NO20064810A patent/NO20064810L/no not_active Application Discontinuation
-
2008
- 2008-10-08 US US12/247,263 patent/US20090099143A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ECSP066877A (es) | 2006-11-24 |
CN1956964A (zh) | 2007-05-02 |
EP1735286B1 (en) | 2012-01-04 |
EA200601760A1 (ru) | 2007-02-27 |
NO20064810L (no) | 2006-12-22 |
MXPA06011017A (es) | 2007-03-21 |
CA2561305C (en) | 2013-07-30 |
US7452997B2 (en) | 2008-11-18 |
BRPI0509207A (pt) | 2007-08-28 |
CN1956964B (zh) | 2011-06-15 |
AU2005228868A1 (en) | 2005-10-13 |
CA2561305A1 (en) | 2005-10-13 |
ES2378071T3 (es) | 2012-04-04 |
ZA200608808B (en) | 2008-06-25 |
WO2005095353A1 (en) | 2005-10-13 |
US20050228034A1 (en) | 2005-10-13 |
ATE540027T1 (de) | 2012-01-15 |
TW200602324A (en) | 2006-01-16 |
CR8701A (es) | 2008-11-24 |
IL178290A0 (en) | 2006-12-31 |
PT1735286E (pt) | 2012-03-05 |
AU2005228868B2 (en) | 2012-02-09 |
US20090099143A1 (en) | 2009-04-16 |
EA010887B1 (ru) | 2008-12-30 |
PL1735286T3 (pl) | 2012-06-29 |
JP4825792B2 (ja) | 2011-11-30 |
DK1735286T3 (da) | 2012-04-02 |
JP2007530577A (ja) | 2007-11-01 |
EP1735286A1 (en) | 2006-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR048341A1 (es) | Moduladores cannabinoides de tetrahidro-indazol | |
PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
AR039570A1 (es) | Antagonistas de los receptores de trombina | |
AR068496A1 (es) | Piperidinas sustituidas, una composicion farmaceutica que las comprende y su uso para el tratamiento de enfermedades mediadas por la modulacion de la actividad de gpr119. | |
RS52245B (en) | CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES AND THEIR THErapeutic Use | |
CO6220853A2 (es) | Derivados de pentafluorotiobenzamido acetonitrilo como agentes antiparasitarios | |
AR049894A1 (es) | Derivados de prolina y sus usos como inhibodores de la enzima dipeptidilpeptidasa-iv | |
CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
AR119046A1 (es) | Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR047098A1 (es) | Derivados de arilanilina como agonistas del receptor adrenergico beta2 | |
AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
DOP2009000232A (es) | Metanoisoindoles y dionas de éstos como agentes anti-psicóticos. | |
AR079553A1 (es) | Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros. | |
JP2008526999A5 (es) | ||
AR056980A1 (es) | Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos | |
AR047545A1 (es) | Compuestos derivados de carbonilamino biciclicos como antagonistas del receptor de quimiocina, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos en combinacion con otros agentes terapeuticos para el tratamiento de inflamaciones, enf | |
AR046313A1 (es) | Compuesto de 2-cianopirrolidincarboxamida, un metodo para su obtencion y su empleo en composiciones farmaceuticas y en medicamentos con actividad inhibitoria de la dipeptidil peptidasa-iv (dpp-iv). | |
AR099640A1 (es) | Derivados de pirrolopiridina o pirazolopiridina | |
AR046926A1 (es) | Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer | |
AR067412A1 (es) | Moduladores de propiedades farmaceuticas de productos terapeuticos | |
AR078550A1 (es) | DERIVADOS DE AZETIDINA Y PIPERIDINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO PARA EL TRATAMIENTO DE AFECCIONES MEDIADAS POR LA MODULACIoN DE GPR119 | |
AR072052A1 (es) | Derivados de indano como reguladores del receptor ampa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |